JP2024074801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024074801A5 JP2024074801A5 JP2024029998A JP2024029998A JP2024074801A5 JP 2024074801 A5 JP2024074801 A5 JP 2024074801A5 JP 2024029998 A JP2024029998 A JP 2024029998A JP 2024029998 A JP2024029998 A JP 2024029998A JP 2024074801 A5 JP2024074801 A5 JP 2024074801A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cancer
- cytokine receptor
- chimeric cytokine
- inducible chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637600P | 2018-03-02 | 2018-03-02 | |
| US62/637,600 | 2018-03-02 | ||
| PCT/US2019/020340 WO2019169290A1 (en) | 2018-03-02 | 2019-03-01 | Inducible chimeric cytokine receptors |
| JP2020568943A JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568943A Division JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024074801A JP2024074801A (ja) | 2024-05-31 |
| JP2024074801A5 true JP2024074801A5 (cg-RX-API-DMAC7.html) | 2024-10-11 |
Family
ID=65952060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568943A Active JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
| JP2024029998A Pending JP2024074801A (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568943A Active JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12163169B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3759132A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7526101B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102842692B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111819192A (cg-RX-API-DMAC7.html) |
| AR (1) | AR114273A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019227979B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017734A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3091681A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL276831B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020009051A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007771VA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI897846B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019169290A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| JP7250519B2 (ja) * | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN117384929A (zh) | 2017-03-27 | 2024-01-12 | 新加坡国立大学 | 一种编码由细胞表达的嵌合受体的多核苷酸 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US12163169B2 (en) * | 2018-03-02 | 2024-12-10 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) * | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CA3129862A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| KR20210136041A (ko) * | 2019-03-01 | 2021-11-16 | 알로젠 테라퓨틱스 인코포레이티드 | 구성적으로 활성인 키메라 사이토카인 수용체 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| EP4041893A4 (en) * | 2019-10-08 | 2023-08-30 | Provincial Health Services Authority | CHEMERACY CYTOKINE RECEPTORS |
| KR20220141299A (ko) * | 2020-01-14 | 2022-10-19 | 신테카인, 인크. | Il2 오르토로그 및 사용 방법 |
| PE20221757A1 (es) * | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| WO2021173586A1 (en) * | 2020-02-24 | 2021-09-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer |
| WO2021170666A1 (en) | 2020-02-25 | 2021-09-02 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
| US20230310606A1 (en) * | 2020-07-17 | 2023-10-05 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| EP4267601A1 (en) * | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| WO2022179563A1 (en) * | 2021-02-24 | 2022-09-01 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and compositions for enhanced immunotherapies and methods thereof |
| KR102829018B1 (ko) | 2021-03-03 | 2025-07-04 | 서울대학교산학협력단 | 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도 |
| JP2024515577A (ja) * | 2021-04-07 | 2024-04-10 | プロヴィンシャル ヘルス サービシーズ オーソリティ | 修飾された顆粒球コロニー刺激因子（ｇ－ｃｓｆ）及びこれに結合するキメラサイトカイン受容体 |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| WO2023276395A1 (ja) * | 2021-06-28 | 2023-01-05 | 愛知県 | キメラサイトカイン受容体 |
| US20230110313A1 (en) | 2021-09-17 | 2023-04-13 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4499680A1 (en) | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| AU2023297866A1 (en) * | 2022-06-28 | 2024-12-12 | Resolution Therapeutics Limited | Switch receptors and modified immune cells |
| CA3260970A1 (en) * | 2022-07-11 | 2024-01-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tunable Cytokine Receptor Signaling Domains |
| CN114949000B (zh) * | 2022-08-02 | 2022-10-04 | 卡瑞济(北京)生命科技有限公司 | 麝香提取物及其增强car-t细胞疗效的应用 |
| CN117683139A (zh) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| TW202436337A (zh) | 2023-01-23 | 2024-09-16 | 漢諾威醫學院 | 嵌合抗原受體 |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024263710A1 (en) | 2023-06-20 | 2024-12-26 | Allogene Therapeutics, Inc. | Methods of detection for engineered cells |
| WO2024261480A1 (en) | 2023-06-21 | 2024-12-26 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| AU2024310260A1 (en) * | 2023-06-29 | 2025-12-11 | Dispatch Biotherapeutics, Inc. | Synthetic cytokine receptors |
| WO2025026347A1 (en) * | 2023-07-31 | 2025-02-06 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and methods of use thereof |
| WO2025064779A1 (en) * | 2023-09-20 | 2025-03-27 | University Of Southern California | Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others |
| WO2025076134A1 (en) * | 2023-10-03 | 2025-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025096643A1 (en) * | 2023-11-01 | 2025-05-08 | Baylor College Of Medicine | Reverse fate receptors to enhance the efficacy of engineered t cells |
| WO2025111277A2 (en) * | 2023-11-20 | 2025-05-30 | Carisma Therapeutics Inc. | Compositions and methods relating to redirected soluble modulators |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) * | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ， インコーポレイテッド | 細胞の同時の刺激および濃縮 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US20100203067A1 (en) | 2008-09-22 | 2010-08-12 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| EP2694640B1 (en) * | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| CN114835823A (zh) | 2011-07-29 | 2022-08-02 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
| JP6467406B2 (ja) | 2013-06-05 | 2019-02-13 | ベリカム ファーマシューティカルズ， インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| EP4420663A3 (en) * | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| RU2017115808A (ru) | 2014-10-07 | 2018-11-13 | Селлектис | Способ модуляции активности car-индуцированных иммунных клеток |
| WO2016100241A2 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| US20180002427A1 (en) | 2015-01-26 | 2018-01-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| AU2016248947B2 (en) | 2015-04-13 | 2020-07-16 | Pfizer Inc. | Chimeric Antigen Receptors targeting B-Cell Maturation Antigen |
| US20180318303A1 (en) | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| CN116970630A (zh) | 2016-08-26 | 2023-10-31 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| CN117720665A (zh) | 2016-11-17 | 2024-03-19 | 2赛文缇生物公司 | TGFβ信号转换器 |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| US12163169B2 (en) | 2018-03-02 | 2024-12-10 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| EP3810645A1 (en) | 2018-06-22 | 2021-04-28 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| CA3129862A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| KR20210136041A (ko) | 2019-03-01 | 2021-11-16 | 알로젠 테라퓨틱스 인코포레이티드 | 구성적으로 활성인 키메라 사이토카인 수용체 |
-
2019
- 2019-03-01 US US16/290,388 patent/US12163169B2/en active Active
- 2019-03-01 CA CA3091681A patent/CA3091681A1/en active Pending
- 2019-03-01 KR KR1020207027009A patent/KR102842692B1/ko active Active
- 2019-03-01 AR ARP190100529A patent/AR114273A1/es unknown
- 2019-03-01 SG SG11202007771VA patent/SG11202007771VA/en unknown
- 2019-03-01 KR KR1020257025809A patent/KR20250123938A/ko active Pending
- 2019-03-01 JP JP2020568943A patent/JP7526101B2/ja active Active
- 2019-03-01 MX MX2020009051A patent/MX2020009051A/es unknown
- 2019-03-01 EP EP19713907.4A patent/EP3759132A1/en active Pending
- 2019-03-01 WO PCT/US2019/020340 patent/WO2019169290A1/en not_active Ceased
- 2019-03-01 BR BR112020017734-2A patent/BR112020017734A2/pt unknown
- 2019-03-01 CN CN201980016890.6A patent/CN111819192A/zh active Pending
- 2019-03-01 AU AU2019227979A patent/AU2019227979B2/en active Active
- 2019-03-01 IL IL276831A patent/IL276831B2/en unknown
- 2019-03-01 IL IL317065A patent/IL317065A/en unknown
- 2019-03-04 TW TW108107136A patent/TWI897846B/zh active
-
2020
- 2020-08-31 MX MX2025009955A patent/MX2025009955A/es unknown
-
2024
- 2024-02-29 JP JP2024029998A patent/JP2024074801A/ja active Pending
- 2024-10-16 US US18/917,035 patent/US20250333719A1/en active Pending
- 2024-12-04 AU AU2024278090A patent/AU2024278090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024074801A5 (cg-RX-API-DMAC7.html) | ||
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7394093B2 (ja) | スイッチ共刺激受容体 | |
| Ferluga et al. | Simultaneous targeting of Eph receptors in glioblastoma | |
| US11980640B2 (en) | Bicistronic chimeric antigen receptors and their uses | |
| JP2022109953A5 (cg-RX-API-DMAC7.html) | ||
| US12152079B2 (en) | Nucleic acids encoding IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy | |
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| CN105331586B (zh) | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 | |
| JPWO2019169290A5 (cg-RX-API-DMAC7.html) | ||
| IL276831B1 (en) | Inducible chimeric cytokine receptors | |
| JP2019534246A5 (cg-RX-API-DMAC7.html) | ||
| US12030957B2 (en) | PLAP-CAR-effector cells | |
| WO2013185552A1 (zh) | 双信号独立的嵌合抗原受体及其用途 | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| Siegemund et al. | IgG-single-chain TRAIL fusion proteins for tumour therapy | |
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| Hussein et al. | TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma | |
| JPWO2020193767A5 (cg-RX-API-DMAC7.html) | ||
| Watanabe et al. | Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma | |
| US20230242607A1 (en) | Il-2 variants | |
| JP2023089182A (ja) | 腫瘍状微小環境を変調する方法 | |
| Tardif et al. | Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia | |
| JPWO2021034976A5 (cg-RX-API-DMAC7.html) |